Leading AI solution for prostate cancer pathway optimization
Advancing the prostate cancer pathway with AI to support physicians, reduce costs, and deliver better care.
%
SENSITIVITY
%
SPECIFICITY
Pi™ matches the accuracy of expert radiologists
The results of a major collaborative research study with 8 UK NHS hospitals, PAIR-1, have been published in the leading journal European Radiology. This study is a landmark in the development and validation of AI for prostate cancer, showing for the first time that Pi™ operates at the level of expert radiologists working in multi-disciplinary teams, across real-world, multi-centre data encompassing different MRI scanner vendors, models and field strengths.This found that Pi™ has outstanding accuracy to detect clinically significant prostate cancer on representative, held-out validation data, with 95% sensitivity and 67% specificity. This high performance allows Pi™ to be used to help find more cancers, rule out patients who do not need further investigations, and save resources and time
What clinicians say
‘Pi can identify the most clinically significant cancers and essentially allow me to offer a same day pathway to those patients. MRi in the morning, biopsy in the afternoon
Dr Oliver Hulson
Consultant Interventional Radiologist
St James University Hospital Leeds
Trusted by our partners
Latest News
Lucida Medical has secured £2.25 million in funding from the Small Business Research Initiative (SBRI)
Macmillan Cancer Support is investing in Lucida Medical, a spin-off from the University of Cambridge that develops Pi™ software to help radiologists find cancer
Lucida Medical Ltd announces a distribution agreement with Sectra to offer Pi AI technology to help diagnose prostate cancer
Somerset’s NHS pioneers clinical use of AI software to transform prostate cancer diagnosis
Blackford and Lucida Medical partner to enhance prostate care
Lucida Medical has changed its brand identity to strengthen its position as a trusted leader in prostate cancer diagnostics.
Upcoming conferences
Find out more at these events:
Get in touch, book a demo
To find out more, please contact us via this form